


Stabilis



Vinblastine sulfate











Noms commerciaux

Blestinib	Mexique
Cytoblastin	Egypte, Malaisie
Lemblastine	Chili, Colombie, Mexique
Oncoblastin	Colombie
Uniblastin	Pérou
VBlastin	Inde
Velbe	Arabie Saoudite, Australie, Autriche, Chili, Danemark, Emirats Arabes Unis, Finlande, France, Grande Bretagne, Grèce, Italie, Luxembourg, Maroc, Norvège, Pays bas, Suède,
Velblastin	Egypte, Malaisie
Vinblasine	Luxembourg
Vinblastin	Hongrie, Pologne
Vinblastina	Argentine, Chili, Colombie, Equateur, Espagne, Mexique, Pérou, Roumanie
Vinblastine	Arabie Saoudite, Australie, Belgique, Canada, Etats Unis d'Amérique, France, Grande Bretagne, Iran, Irlande, Nouvelle Zélande, Pays bas, Tunisie
Vinblastinsulfat	Allemagne
Vinblatine	Malaisie
Vinko	Turquie












Stabilité des solutions

?	?	[]	- +	?	⏰	Y	!	📖
		1 mg/ml	4°C		21			481
		0,05 mg/ml	2-8°C		21			1727
		0,05 mg/ml	21-25°C		21			1727
		0,1 mg/ml	4°C		7			144
		0,02 mg/ml	25°C		21			481
		0,02 mg/ml	4°C		21			481
	RL	0,02 mg/ml	25°C		21			481
	RL	0,02 mg/ml	4°C		21			481

		1 mg/ml	21°C		30			1229
		1 mg/ml	6°C-9°C		30			1229




































Facteur influençant la stabilité

	Nylon			167
				827 1009
	2 < pH < 4			1157



Compatibilités

			
	Vinblastine sulfate : 0.12 mg/ml Allopurinol sodium : 3 mg/ml		307
	Vinblastine sulfate : 0.12 mg/ml Amifostine : 10 mg/ml		3
	Vinblastine sulfate : 0.12 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Vinblastine sulfate : 0.12 mg/ml Aztreonam : 40 mg/ml		99
	 Vinblastine sulfate Calcium gluconate		3644
	 Vinblastine sulfate Cisplatin		3578
	Vinblastine sulfate : 1 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
	Vinblastine sulfate : 0.12 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Vinblastine sulfate : 1 mg/ml Droperidol : 2,5 mg/ml		763
	Vinblastine sulfate : 0.12 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Vinblastine sulfate : 0.12 mg/ml Filgrastim : 30 µg/ml		244
	Vinblastine sulfate : 1 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Vinblastine sulfate : 1 mg/ml Fluorouracil : 50 mg/ml		763
	Vinblastine sulfate : 1 mg/ml Folate calcium : 10 mg/ml		763
	 Vinblastine sulfate : 1 mg/ml Furosemide : 10 mg/ml		763
	Vinblastine sulfate : 0.12 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Vinblastine sulfate : 0.12 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182

	Vinblastine sulfate : 1 mg/ml Heparin sodium : 1000 UI/ml		763
	Vinblastine sulfate Heparin sodium		3540
	Vinblastine sulfate : 0.12 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Vinblastine sulfate : 0.12 mg/ml Melphalan : 0.1 mg/ml		169
	Vinblastine sulfate : 1 mg/ml Methotrexate sodium : 25 mg/ml		763
	Vinblastine sulfate : 1 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
	Vinblastine sulfate : 0.12 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Vinblastine sulfate : 0.12 mg/ml Paclitaxel : 1.2 mg/ml		248
	Vinblastine sulfate : 0.12 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Vinblastine sulfate : 0.12 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Vinblastine sulfate : 0.12 mg/ml Sargramostim : 10 µg/ml		335
	Vinblastine sulfate : 0.12 mg/ml Teniposide : 0.1 mg/ml		905
	Vinblastine sulfate : 0.12 mg/ml Thiotepa : 1 mg/ml		249
	Vinblastine sulfate : 1 mg/ml Vincristine sulfate : 1 mg/ml		763
	Vinblastine sulfate : 0.12 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.

99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144	Revue	Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285.
167	Revue	Francomb MM, Ford JL, Lee MG. Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. Int J Pharm 1994 ; 103: 87-92.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
481	Revue	Beijnen JH, Vendrig DEMM, Underberg WJM. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 1989 ; 43: 84-87.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
763	Revue	Cohen MH, Johnson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
827	Revue	Black J, Buechter DD, Thurston DE. Stability of vinblastine sulfate when exposed to light. Drug Intell Clin Pharm 1988 ; 22: 634-636.

905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1009	Revue	Black J, Buechter DD, Chinn JW, Gard J, Thurston DE. Studies on the stability of vinblastine sulfate in aqueous solution. J Pharm Sci 1988 ; 77: 630-634.
1157	Revue	Vendrig DEMM, Smeets BPGM, Beijnen JH, van der Houwen OAGJ, Holthuis JJM. Degradation kinetics of vinblastine sulphate in aqueous solutions. Int J Pharm 1988 ; 43: 131-138.
1229	Revue	Weir PJ, Ireland DS. Chemical stability of cytarabine and vinblastine injections. Br J Pharm Pract 1990 ; 12: 53-54, 60.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1727	Revue	Mittner A, Vincze Z, Jemnitz K. Stability of vinblastine sulphate containing infusions. Pharmazie 1999 ; 54: 625-626.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 A l'abri de la lumière
 Jour	 Chlorure de sodium 0,9%
 Polyvinyl chlorure	 NaCl 0,9% ou glucose 5%
 Polypropylène	RL Ringer lactate
 Seringue polypropylène	 Facteur influençant la stabilité
 Filtration	 Provoque
 Adsorption	 Lumière
 Dégradation	 Augmentation stabilité
 Compatibilités	 Molécule
 Solvant	 Compatible
 Glucose 5%	 Incompatibilité non précisée
 Incompatible	 Instabilité chimique
 Précipitation immédiate	 Voie d'administration
 Intraveineuse	 Perfusion continue
 Bibliographie	 Dictionnaire